CN102725311A - 治疗发炎的方法 - Google Patents

治疗发炎的方法 Download PDF

Info

Publication number
CN102725311A
CN102725311A CN2010800526286A CN201080052628A CN102725311A CN 102725311 A CN102725311 A CN 102725311A CN 2010800526286 A CN2010800526286 A CN 2010800526286A CN 201080052628 A CN201080052628 A CN 201080052628A CN 102725311 A CN102725311 A CN 102725311A
Authority
CN
China
Prior art keywords
peptide
mif
ring
primitive
structural domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800526286A
Other languages
English (en)
Chinese (zh)
Inventor
于尔根·伯恩哈根
克里斯蒂安·韦伯
贝内迪克特·福尔拉特
考特·特纳
乔舒亚·罗伯特·舒尔茨
阿尔玛·策内克
塞尔希奥·杜龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolus Therapeutics Inc
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of CN102725311A publication Critical patent/CN102725311A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2010800526286A 2009-09-23 2010-09-23 治疗发炎的方法 Pending CN102725311A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US61/245,214 2009-09-23
US31903910P 2010-03-30 2010-03-30
US61/319,039 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (1)

Publication Number Publication Date
CN102725311A true CN102725311A (zh) 2012-10-10

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800526286A Pending CN102725311A (zh) 2009-09-23 2010-09-23 治疗发炎的方法

Country Status (9)

Country Link
EP (1) EP2480579A4 (https=)
KR (1) KR20120105429A (https=)
CN (1) CN102725311A (https=)
AU (1) AU2010298249A1 (https=)
BR (1) BR112012006468A2 (https=)
CA (1) CA2773978A1 (https=)
IN (1) IN2012DN02423A (https=)
MX (1) MX2012003514A (https=)
WO (1) WO2011038149A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用
CN113383235A (zh) * 2018-12-26 2021-09-10 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物
CN119318647A (zh) * 2024-08-14 2025-01-17 南方医科大学 Sb225002在制备治疗心肌梗死的药物中的应用、治疗心肌梗死的组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2849788B1 (en) * 2012-05-17 2018-01-03 Cyon Therapeutics Inc. Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
AR098418A1 (es) * 2013-11-14 2016-05-26 Baxter Healthcare Sa Factor inhibitorio de imigración de macrófago (mif) como objetivo terapéutico
CN109152780B (zh) 2016-03-11 2021-10-01 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
CA3174634A1 (en) * 2020-03-11 2021-09-16 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
WO2021219495A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
US12558549B2 (en) 2022-10-28 2026-02-24 Medtronic, Inc. Lead based measurements for tongue movement determination
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes
US20040115193A1 (en) * 2002-03-01 2004-06-17 Immunomedics, Inc. Internalizing anti-CD-74 antibodies and methods of use
EP1724286A1 (en) * 2005-05-17 2006-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Variant CD44 polypeptide, polynucleotides encoding same, antibodies directed there against and method of using same for diagnosing and treating inflammatory diseases
WO2009117710A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897349B2 (en) * 2003-12-30 2011-03-01 The United States Of America As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes
US20040115193A1 (en) * 2002-03-01 2004-06-17 Immunomedics, Inc. Internalizing anti-CD-74 antibodies and methods of use
EP1724286A1 (en) * 2005-05-17 2006-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Variant CD44 polypeptide, polynucleotides encoding same, antibodies directed there against and method of using same for diagnosing and treating inflammatory diseases
WO2009117710A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113383235A (zh) * 2018-12-26 2021-09-10 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用
CN119318647A (zh) * 2024-08-14 2025-01-17 南方医科大学 Sb225002在制备治疗心肌梗死的药物中的应用、治疗心肌梗死的组合物

Also Published As

Publication number Publication date
WO2011038149A3 (en) 2011-10-27
AU2010298249A1 (en) 2012-04-19
BR112012006468A2 (pt) 2016-08-09
EP2480579A4 (en) 2013-07-31
MX2012003514A (es) 2012-04-19
KR20120105429A (ko) 2012-09-25
IN2012DN02423A (https=) 2015-08-21
WO2011038149A2 (en) 2011-03-31
CA2773978A1 (en) 2011-03-31
EP2480579A2 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
CN102725311A (zh) 治疗发炎的方法
TWI906906B (zh) 抗ccr8抗體及其用途
US20240352135A1 (en) Antibodies and polypeptides directed against cd127
TWI857389B (zh) 治療發炎症狀的方法
CN102088993A (zh) 炎症的治疗方法
EP2623592B1 (en) Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier
JP6649941B2 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
JP2019504064A (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用方法
KR20110074898A (ko) 염증을 치료하는 방법
TW200927760A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
US20240199732A1 (en) Anti-IL-27 Antibodies and Uses Thereof
CN102395602B (zh) 在疾病治疗方法中使用的b‑淋巴细胞靶向剂
CN110945128B (zh) 用于治疗肺纤维化的组合物和方法
JP2021505659A (ja) 癌治療のためのｔｒｐｖ６阻害剤および併用療法
TW202021983A (zh) 用於嗜伊紅性氣喘之抗il-33療法
EP4549572A1 (en) Fusion protein
WO2025007057A2 (en) Lymphocyte trafficking receptor and ligand
BR112022006760B1 (pt) Anticorpo anti-receptor semelhante a quemerina 1 ou fragmentos de ligação ao antígeno do mesmo e usos preventivos ou terapêuticos do mesmo
HK40107088A (zh) 用於评价发展急性covid-19和急性後covid-19的风险的生物标志物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121010